Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions, with a primary focus on photodynamic therapy (PDT). The company's mission is to become a leading U.S. specialty dermatology company by offering innovative therapy options that empower healthcare professionals to enhance patient lives. Its headquarters are located in Woburn, Massachusetts.

The company's key product portfolio centers on Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, which is used in combination with its proprietary RhodoLED® and BF-RhodoLED® XL red light lamps for photodynamic therapy. This drug-device combination is primarily indicated for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. Biofrontera Inc. is actively expanding its market segments, pursuing additional indications for Ameluz®-PDT, including superficial basal cell carcinoma (sBCC) and moderate to severe acne.

A significant development in 2025 saw Biofrontera Inc. acquire all U.S. rights to Ameluz® and RhodoLED® from its former parent company, Biofrontera AG. This strategic acquisition transitioned the company from a distribution model with high transfer pricing to a more favorable royalty-based agreement, aiming to significantly improve gross margins and accelerate profitability. Additionally, the company divested its Xepi® antibiotic cream to concentrate on its core photodynamic therapy business. Under the leadership of CEO and Chairman Prof. Dr. Hermann Luebbert, Biofrontera Inc. reported positive Phase 2b results for Ameluz® PDT in moderate to severe acne vulgaris in March 2026, further solidifying its market positioning as an integrated, high-margin leader in the U.S. dermatology sector.